Switch to Atazanavir-RTV with Either Raltegravir or TDF-FTC

HARNESS Trial
Switch to Atazanavir-ritonavir with Either Raltegravir or TDF-FTC

HARNESS: Study Design

**Study Design: HARNESS**

**Background**: Open label, prospective, randomized, parallel group trial evaluating switching from stable ARV regimen (2 NRTIs + 3rd agent, excluding atazanavir) to ritonavir-boosted atazanavir with either raltegravir 400 mg BID or TDF-FTC.

**Inclusion Criteria (n = 109)**
- Age ≥ 18 years
- HIV RNA < 50 copies/mL for ≥ 3 months
- Single HIV RNA < 40 copies/mL in past 30 days
- No history of virologic failure or resistance

**Treatment Arms**
- Atazanavir + RTV QD + Raltegravir 400 mg BID
- Atazanavir + RTV QD + TDF-FTC QD

Switch to Atazanavir-ritonavir with Raltegravir or TDF-FTC

HARNESS: Results

Week 24 and 48: Virologic Response (Intent-to-Treat Analysis)

Switch to Atazanavir-ritonavir with Raltegravir or TDF-FTC

HARNESS: Results

Week 24 and 48: Virologic Rebound

Conclusion: “In conclusion, switching to ATV/r + RAL resulted in a higher virological rebound rate than switching to ATV/r plus tenofovir disoproxil fumarate/emtricitabine.”

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.